2. ВИЧ-инфекция у взрослых: Клинические рекомендации. Министерство здравоохранения Российской Федерации, 2020. https://cr.minzdrav.gov.ru/recomend/79_1

(HIV infection in adults: Clinical guidelines). Ministry of Health of the Russian Federation, 2020. (In Russ.). https://cr.minzdrav.gov.ru/ recomend/79_1

3. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Буравцова Е.В., Деулина М.О. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Эпидемиол. инфекц. болезни. Актуал. вопр. 2022; 12(4, приложение). 108 с.

Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Buravtsova E.V., Deulina M.O. et al. (Recommendations for the treatment of HIV infection and related diseases, chemoprevention of HIV infection). Epidemiology and infectious diseases. Current items 2022; 12(4, appendix). 108 p. (In Russ.).

4. Department of Health and Human Services USA. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2023. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf

5. European AIDS Clinical Society. Guidelines, Version 11.0, October 2021. https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf

6. WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV, 2018. https://www.who.int/publications/i/item/ WHO-CDS-HIV-18.51

7. Aydin E., Aydin Yi.F., Demir Y., Yildirim Y., Celen M.K. Evaluation of kidney function tests in HIV‐positive patients receiving combined antiretroviral therapy. Int. J. Clin. Pract. 2021; 75(8): e14542. doi: 10.1111/ijcp.14542

8. Brown T.T., Qaqish R.B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20(17), pp.2165-2174

9. Lipshultz S.E., Mas C.M., Henkel J.M., Franco V.I., Fisher S.D., Miller T.L. HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults. Expert Rev. Anti. Infect. Ther. 2012; 10(6): 661–74. doi: 10.1586/eri.12.53

10. Nduka C.U., Stranges S., Kimani P.K., Sarki A.M., Uthman O.A. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes Metab. Res. Rev. 2017; 33(6). doi: 10.1002/dmrr.2902

11. Back D., Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J. Int. AIDS Soc. 2020; 23(2): e25449. doi: 10.1002/jia2.25449

12. Веселова Е.И., Каминский Г.Д., Карамов Э.В., Кудлай Д.А., Орлова-Морозова Е.А., Ловачева О.В., Самойлова А.Г. Эффективность и безопасность лечения ВИЧ-инфекции с переходом на битерапию после 24 недель тритерапии. Инфекционные болезни: новости, мнения, обучение 2021; 10(4): 66–75. doi: https://doi.org/10.33029/2305-3496-2021-10-4-66-75

Veselova E.I., Kaminsky G.D., Karamov E.V., Kudlai D.A., Orlova-Morozova E.A., Lovacheva O.V., Samoilova A.G. (Switching to dual therapy after 24 weeks of the triple therapy of HIV infection: efficacy and safety). Infectious diseases: news, opinions, training 2021; 11(4): 66–75. doi: https://doi.org/10.33029/2305-3496-2021-10-4-66-75

13. Канестри В.Г., Кравченко А.В., Покровская А.В., Кулабухова Е.И., Куимова У.А., Голиусова М.Д. и др. Рандомизированное открытое контролируемое сравнительное исследование по переключению больных ВИЧ-инфекцией с опытом антиретро­вирусной терапии на схему, включавшую DTG и 3ТС: результаты 96 недель. Эпидемиол. инфекц. болезни. Актуал. вопр. 2021; 11(4): 45–52. doi: https://dx.doi.org/10.18565/epidem.2021.11.4.45-52

Kanestri V.G., Kravchenko A.V., Pokrovskaya A.V., Kulabukhova E.I., Kuimova U.A., Goliusova M.D. et al. (Randomized, open-label, controlled, comparative study on switching HIV-infected patients with their antiretroviral therapy experience to a DTG and 3TC regimen: 96-weeks results). Epidemiology and infectious diseases. Current Items 2021; 11(4): 45–52. (In Russ.). doi: https://dx.doi.org/10.18565/epidem.2021.11.4.45-52

14. Bennett L., Rose D., Jackson A., Thomas S. Psychological and socio-medical aspects of HIV/AIDS: a reflection on publications in AIDS care (1989–1995). AIDS Care 1998; 10(1): 115–21.

15. Беляева В.В., Козырина Н.В., Соколова Е.В., Семикова С.Ю., Галиуллин Н.И., Лебедева Е.П. и др. Анализ факторов риска нарушения приверженности диспансерному наблюдению и лечению ВИЧ-инфекции: оценка готовности следовать рекомендациям специалистов. Эпидемиол. инфекц. бол. Актуал. вопр. 2021; 11(3): 63–8. DOI: 10.18565/epidem.2021.11.3.63-8

Belyaeva V.V., Kozyrina N.V., Sokolova E.V., Semikova S. Yu., Galiullin N.I., Lebedeva E.P. et al. (Analysis of risk factors for non-adherence to follow-up and treatment for HIV infection: assessment of readiness to follow specialists’ recommendations). Epidemiology and infectious diseases. Current items 2021; 11(3): 63–8. (In Russ.). DOI: 10.18565/epidem. 2021.11.3.63-8

16. Girouard M.P., Sax P.E., Parker R.A., Taiwo B., Freedberg K.A., Gulick R.M. et al. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clin. Infect. Dis. 2016; 62(6): 784–91. doi: 10.1093/cid/civ981

17. Cahn P., Madero J.S., Arribas J.R., Antinori A., Ortiz R., Clarke A.E. et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019; 393(10167): 143–55. doi: 10.1016/S0140-6736(18)32462-0

18. Cahn P., Madero J.S., Arribas J.R., Antinori A., Ortiz R., Clarke A.E. et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment–naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. Journal of Acquired Immune Deficiency Syndromes (JAIDS) 2020; 83(3): 310–8. doi: 10.1097/qai.0000000000002275

19. Cahn P., Sierra Madero J., Arribas J.R., Antinori A. et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy–naive adults with HIV-1 infection. AIDS 2022; 36(1): 39–48. doi: 10.1097/QAD.0000000000003070

20. Quercia R., Roberts J., Martin-Carpenter L., Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin. Drug. Investig. 2015; 35(3): 211–9. doi: 10.1007/s40261-014-0266-2

21. Cottrell M.L., Hadzic T., Kashuba A.D. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clinical Pharmacokinetics 2013; 52(11): 981–94. doi: 10.1007/s40262-013-0093-2

22. Milburn J., Jones R., Levy J.B. Renal effects of novel antiretroviral drugs. Nephrol. Dial. Transplant. 2017; 32(3): 434–9. doi: 10.1093/ndt/gfw064

23. Diaco N.D., Strickler C., Giezendanner S., Wirz S.A., Tarr P.E. Systematic de-escalation of successful triple antiretroviral therapy to dual therapy with dolutegravir plus emtricitabine or lamivudine in Swiss HIV-positive persons. EClinicalMedicine. 2018; 6: 21–5. doi: 10.1016/j.eclinm.2018.11.005

24. Elzi L., Erb S., Furrer H., Cavassini M., Calmy A., Vernazza P., Günthard H., Bernasconi E., Battegay M. Adverse events of raltegravir and dolutegravir. AIDS, 2017; 31(13): 1853–8. doi: 10.1097/QAD. 0000000000001590

25. Peñafiel J., de Lazzari E., Padilla M., Rojas J., Gonzalez-Cordon A., Blanco J.L. et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017; 72(6): 1752–9. doi: 10.1093/jac/dkx053

26. Baldin G., Ciccullo A., Rusconi S., Capetti A., Sterrantino G., Colafigli M. et al. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int. J. Antimicrob. Agents 2019; 54(6): 728–34. doi: 10.1016/j.ijantimicag.2019.09.002

27. Bonfanti P., Madeddu G., Gulminetti R., Squillace N., Orofino G., Vitiello P. et al. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS 2017 31(3): 455–7. doi: 10.1093/ndt/gfw064

28. Hoffmann C., Welz T., Sabranski M., Kolb M., Wolf E., Stellbrink H.J. et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017; 18(1): 56–63. doi: 10.1111/hiv.12468

29. Bourgi K., Rebeiro P.F., Turner M., Castilho J.L., Hulgan T., Raffanti S.P. et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin/ Infect/ Dis. 2020; 70(7): 1267–74. doi: 10.1093/cid/ciz407

30. Rizzardo S., Lanzafame M., Lattuada E., Luise D., Vincenzi M., Tacconelli E. et al. Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients. AIDS 2019; 33(10): 1673–4. doi:10.1097/QAD. 0000000000002245

31. Кравченко А.В., Канестри В.Г. Проблема увеличения массы тела у больных ВИЧ-инфекцией в процессе антиретровирусной терапии. Эпидемиол. инфекц. болезни. Актуал. вопр. 2020; 10(3): 112–5. doi: https://dx.doi.org/10.18565/epidem.2020.10.3.112-5

Kravchenko A.V., Kanestri V.G. (The problem of weight gain in patients with HIV infection during antiretroviral therapy). Epidemiology and infectious diseases. Current items 2020; 10(3): 112–5. (In Russ.). doi: https://dx.doi.org/10.18565/epidem.2020.10.3.112-5

32. Moure R., Domingo P., Gallego-Escuredo J.M., Villarroya J., del Mar Gutierrez M., Mateo M.G. et al. Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines. Antiviral Res. 2016; 132: 59–65. doi: 10.1016/j.antiviral. 2016.05.013

33. Gu L., Han Y., Li Y., Zhu T., Song X., Huang Y. et al. Emergence of lamivudine-resistant HBV during antiretroviral therapy including lamivudine for patients coinfected with HIV and HBV in China. PloS ONE 2015; 10(8): e0134539. doi: 10.1371/journal.pone.0134539

34. Lok A.S., Ganova‐Raeva L., Cloonan Y., Punkova L., Lin H.H., Lee W.M. et al. Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. J. Viral. Hepat. 2017; 24(11): 1032–42. doi: 10.1111/jvh.12732

35. Ciccullo A., Baldin G., Lombardi F., Borghetti A., Di Giambenedetto S. HIV DNA decay in a treatment-naive patient starting dolutegravir plus lamivudine with resistance mutations to integrase inhibitors: A case report. AIDS Res. Hum. Retroviruses. 2020; 36(4): 256–7. doi: 10.1089/ AID.2019.0270.

36. Zash R., Holmes L., Diseko M., Jacobson D.L., Brummel S., Mayondi G. et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N. Engl. J. Med. 2019; 381(9): 827–40. doi: 10.1056/NEJMoa1905230

37. Llibre J.M., Cahn P.E., Lo J., Barber T.J., Mussini C., van Welzen B.J. et al. Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review. Open Forum Infect. Dis. 2022; 9(4): ofac068. doi: 10.1093/ofid/ofac068

38. Кижло С.Н., Man C.Y., Sievers J., Urbaityte R., Brown D., Кузнецов С.Д. и др. Применение долутегравира и ламивудина в сравнении с применением долутегравира и тенофовира/эмтрицитабина у ранее не получавших лечения взрослых, инфицированных ВИЧ-1: результаты оценки эффективности и безопасности на 48 неделе у участников исследования GEMINI-1/2 в исследовательских центрах в России. Журнал Инфектологии 2019; 11(3, приложение 1): 131–32.

Kizhlo S.N., Man C.Y., Sievers J., Urbaityte R., Brown D., Kuznetsov S.D. et al. (Dolutegravir and lamivudine versus dolutegravir and tenofovir/emtricitabine in previously untreated HIV-1 infected adults: 48-week efficacy and safety results in participants in the GEMINI-1/2 study at research centers in Russia). Journal Infectology 2019; 11(3, appendix 1): 131–32. (In Russ.).